Literature DB >> 6458032

Platelet monoamine uptake in relatives of patients with Huntington's chorea.

R S Ehsanullah, P Turner.   

Abstract

Uptake of dopamine and 5-hydroxytryptamine (5-HT) by the platelets of 25 symptom-free relatives of patients with established Huntington's chorea (HC) was not significantly different from that of control subjects. Platelet uptake of 5-HT in 3 subjects with early signs of the disease showed increased Km and Vmax values. Increased platelet uptake of 5-HT in patients with established HC was confirmed in a further 3 patients. It seems that this phenomenon appears with the clinical evidence of the disease. Further investigation of the nature of the platelet uptake abnormality may cast light on pathogenic factors in HC.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458032      PMCID: PMC2426140          DOI: 10.1136/pgmj.57.670.479

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Plasma uptake of dopamine and 5-hydroxytryptamine and plasma-catecholamine levels in patients with Huntington's chorea.

Authors:  M J Aminoff; A Trenchard; P Turner; W G Wood; M Hills
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

2.  L-dopa and juvenile Huntington's disease.

Authors:  A Barbeau
Journal:  Lancet       Date:  1969-11-15       Impact factor: 79.321

3.  Uptake of dopamine and 5-hydroxytryptamine by platelets from patients with Huntington's chorea.

Authors:  D R McLean; T Nihei
Journal:  Lancet       Date:  1977-01-29       Impact factor: 79.321

4.  Effects of nomifensine in vitro on uptake of 5-hydroxytryptamine and dopamine into human platelets.

Authors:  R S Ehsanullah; P Turner
Journal:  Br J Clin Pharmacol       Date:  1977       Impact factor: 4.335

  4 in total
  1 in total

Review 1.  The current state of research with peripheral tissues in Huntington disease.

Authors:  G C Beverstock
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.